

BET Bromodomain Inhibition Suppresses the Function of Transcription Factors in Acute Myeloid Leukemia

Molecular Cell

58, 1028-1039

DOI: [10.1016/j.molcel.2015.04.011](https://doi.org/10.1016/j.molcel.2015.04.011)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5851.	4.3	21
2	BET bromodomain inhibitors in leukemia. <i>Experimental Hematology</i> , 2015, 43, 718-731.	0.4	33
3	Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 611-623.	11.1	97
4	Open access chemical probes for epigenetic targets. <i>Future Medicinal Chemistry</i> , 2015, 7, 1901-1917.	2.3	47
5	Directly targeting transcriptional dysregulation in cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 686-694.	28.4	95
6	Targeting Transcription Factors in Cancer. <i>Trends in Cancer</i> , 2015, 1, 53-65.	7.4	247
7	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. <i>Nature</i> , 2015, 525, 543-547.	27.8	414
8	NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. <i>Molecular Cell</i> , 2015, 60, 847-859.	9.7	137
9	Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. <i>Molecular Cell</i> , 2015, 60, 561-570.	9.7	47
10	Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia. <i>Oncotarget</i> , 2016, 7, 25208-25223.	1.8	19
11	The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 61-66.	1.1	21
12	BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells. <i>Nucleic Acids Research</i> , 2017, 45, gkw1276.	14.5	22
13	MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation. <i>Leukemia</i> , 2016, 30, 1552-1561.	7.2	18
14	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. <i>Nature Chemical Biology</i> , 2016, 12, 504-510.	8.0	43
15	BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. <i>Cancer Discovery</i> , 2016, 6, 612-629.	9.4	272
16	Phospho-BRD4: transcription plasticity and drug targeting. <i>Drug Discovery Today: Technologies</i> , 2016, 19, 17-22.	4.0	39
17	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8787-8803.	6.4	41
18	Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies. <i>Expert Review of Proteomics</i> , 2016, 13, 929-939.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. <i>Cell Death and Disease</i> , 2016, 7, e2365-e2365.	6.3	40
20	Small-Molecule Targeting of BET Proteins in Cancer. <i>Advances in Cancer Research</i> , 2016, 131, 21-58.	5.0	72
21	BRD4 Phosphorylation Regulates HPV E2-Mediated Viral Transcription, Origin Replication, and Cellular MMP-9 Expression. <i>Cell Reports</i> , 2016, 16, 1733-1748.	6.4	74
22	Bromodomain 4: a cellular Swiss army knife. <i>Journal of Leukocyte Biology</i> , 2016, 100, 679-686.	3.3	87
23	Erythropoiesis provides a BRD's eye view of BET protein function. <i>Drug Discovery Today: Technologies</i> , 2016, 19, 23-28.	4.0	16
24	AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2563-2574.	4.1	123
25	Palmitate-induced Endoplasmic Reticulum stress and subsequent C/EBP β Homologous Protein activation attenuates leptin and Insulin-like growth factor 1 expression in the brain. <i>Cellular Signalling</i> , 2016, 28, 1789-1805.	3.6	43
26	Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. <i>Blood</i> , 2016, 127, 3040-3053.	1.4	60
27	Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. <i>Nature Communications</i> , 2016, 7, 11624.	12.8	1,238
28	Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of <i>MLL</i> -rearranged AML. <i>Science Signaling</i> , 2016, 9, ra91.	3.6	63
29	Inhibition of interleukin-3- and interferon- γ -induced JAK/STAT signaling by the synthetic β -X-2 β ,3,4,4 β -tetramethoxychalcones β -Br-TMC and β -CF ₃ -TMC. <i>Biological Chemistry</i> , 2016, 397, 1187-1204.	3.5	6
30	MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program. <i>Cell Discovery</i> , 2016, 2, 16008.	6.7	34
31	Regulatory Enhancer β -Core-Promoter Communication via Transcription Factors and Cofactors. <i>Trends in Genetics</i> , 2016, 32, 801-814.	6.7	153
32	Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes. <i>Cell Reports</i> , 2016, 15, 310-322.	6.4	38
33	BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. <i>Cell Reports</i> , 2016, 15, 519-530.	6.4	126
34	Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4. <i>Structure</i> , 2016, 24, 1201-1208.	3.3	54
35	Functional interdependence of BRD4 and DOT1L in MLL leukemia. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 673-681.	8.2	92
36	Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. <i>BMC Molecular Biology</i> , 2016, 17, 10.	3.0	41

#	ARTICLE	IF	CITATIONS
37	Regulation of mammalian transcription and splicing by Nuclear RNAi. <i>Nucleic Acids Research</i> , 2016, 44, 524-537.	14.5	104
38	A Biologist's Field Guide to Multiplexed Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1489-1497.	3.8	50
39	An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. <i>Nature Genetics</i> , 2016, 48, 265-272.	21.4	216
40	C/EBP β creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4. <i>Nature Cell Biology</i> , 2016, 18, 371-381.	10.3	94
41	Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 783-799.	3.4	50
42	Combinatorial function of transcription factors and cofactors. <i>Current Opinion in Genetics and Development</i> , 2017, 43, 73-81.	3.3	269
43	MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. <i>Oncogene</i> , 2017, 36, 3346-3356.	5.9	86
44	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017, 17, 160-183.	28.4	76
45	Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2476-2487.	0.9	173
46	Targeting Cancer Cells with BET Bromodomain Inhibitors. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026674.	6.2	151
47	Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. <i>Blood</i> , 2017, 130, 48-58.	1.4	143
48	Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBP β . <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1349-1358.	4.1	15
49	PAX3 β FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. <i>Cancer Discovery</i> , 2017, 7, 884-899.	9.4	221
50	Click chemistry enables preclinical evaluation of targeted epigenetic therapies. <i>Science</i> , 2017, 356, 1397-1401.	12.6	120
51	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. <i>Nature Neuroscience</i> , 2017, 20, 1052-1061.	14.8	330
52	The BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries. <i>Molecular Cell</i> , 2017, 66, 102-116.e7.	9.7	114
53	N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment. <i>Scientific Reports</i> , 2017, 7, 42108.	3.3	22
54	Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. <i>Leukemia</i> , 2017, 31, 1951-1961.	7.2	151

#	ARTICLE	IF	CITATIONS
55	Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation. <i>Journal of Biological Chemistry</i> , 2017, 292, 17225-17235.	3.4	17
56	miR-150 Regulates Memory CD8 ⁺ Cell Differentiation via c-Myb. <i>Cell Reports</i> , 2017, 20, 2584-2597.	6.4	70
57	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT/mTORC1 activation. <i>Nature Medicine</i> , 2017, 23, 1055-1062.	30.7	225
58	Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival. <i>Nature Communications</i> , 2017, 8, 1707.	12.8	86
59	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. <i>Molecular Cell</i> , 2017, 68, 731-744.e9.	9.7	90
60	Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208). <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 337-347.	2.4	39
61	BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma. <i>Biological Research</i> , 2017, 50, 19.	3.4	38
62	BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. <i>Nucleic Acids Research</i> , 2017, 45, 127-141.	14.5	90
63	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. <i>Leukemia</i> , 2017, 31, 678-687.	7.2	77
64	Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. <i>Molecular Cancer Research</i> , 2017, 15, 35-44.	3.4	54
65	RUNX2 expression in thyroid and breast cancer requires the cooperation of three non-redundant enhancers under the control of BRD4 and c-JUN. <i>Nucleic Acids Research</i> , 2017, 45, 11249-11267.	14.5	57
66	Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis. <i>Nature Communications</i> , 2017, 8, 2217.	12.8	161
67	Developmental Control of NRAMP1 (SLC11A1) Expression in Professional Phagocytes. <i>Biology</i> , 2017, 6, 28.	2.8	11
68	Targeting BET bromodomains in hematological malignancies. <i>Hematologie</i> , 2017, 23, 33-42.	0.0	0
69	Depletion of Mediator Kinase Module Subunits Represses Superenhancer-Associated Genes in Colon Cancer Cells. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	18
70	Assessing sufficiency and necessity of enhancer activities for gene expression and the mechanisms of transcription activation. <i>Genes and Development</i> , 2018, 32, 202-223.	5.9	171
71	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. <i>Oncogene</i> , 2018, 37, 2687-2701.	5.9	66
72	Enhancer variants reveal a conserved transcription factor network governed by PU.1 during osteoclast differentiation. <i>Bone Research</i> , 2018, 6, 8.	11.4	30

#	ARTICLE	IF	CITATIONS
73	BET bromodomain proteins regulate enhancer function during adipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2144-2149.	7.1	65
74	Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Chemical Reviews, 2018, 118, 1216-1252.	47.7	236
75	Rev-erb α dynamically modulates chromatin looping to control circadian gene transcription. Science, 2018, 359, 1274-1277.	12.6	171
76	Enhancer dysfunction in leukemia. Blood, 2018, 131, 1795-1804.	1.4	29
77	BET Proteins as Targets for Anticancer Treatment. Cancer Discovery, 2018, 8, 24-36.	9.4	345
78	Super-enhancers define a proliferative PGC-1 α -expressing melanoma subgroup sensitive to BET inhibition. Oncogene, 2018, 37, 512-521.	5.9	33
79	A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell, 2018, 33, 13-28.e8.	16.8	61
80	Peptidomimetic blockade of MYB in acute myeloid leukemia. Nature Communications, 2018, 9, 110.	12.8	68
81	BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells. Haematologica, 2018, 103, 939-948.	3.5	23
82	BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia, 2018, 32, 343-352.	7.2	127
83	An Overview of the Advantages of KEAP1-NRF2 System Activation During Inflammatory Disease Treatment. Antioxidants and Redox Signaling, 2018, 29, 1746-1755.	5.4	65
84	Cystathionine gamma-lyase/hydrogen sulfide system is essential for adipogenesis and fat mass accumulation in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 165-176.	2.4	50
85	Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia. Cancer Research, 2018, 78, 1097-1109.	0.9	19
86	What Is the BET on Solid Tumors?. Journal of Clinical Oncology, 2018, 36, 3040-3042.	1.6	10
87	Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget, 2018, 9, 11665-11676.	1.8	14
88	BRD4 and Cancer: going beyond transcriptional regulation. Molecular Cancer, 2018, 17, 164.	19.2	414
89	Brd4 α 's Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1. Cell Reports, 2018, 25, 1756-1771.	6.4	74
90	Epigenomic Control of Thermogenic Adipocyte Differentiation and Function. International Journal of Molecular Sciences, 2018, 19, 1793.	4.1	9

#	ARTICLE	IF	CITATIONS
91	Novel flavagline-like compounds with potent Fli-1 inhibitory activity suppress diverse types of leukemia. <i>FEBS Journal</i> , 2018, 285, 4631-4645.	4.7	22
92	Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors. <i>ChemMedChem</i> , 2018, 13, 1363-1368.	3.2	6
93	Eukaryotic core promoters and the functional basis of transcription initiation. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 621-637.	37.0	480
94	Gene-specific mechanisms direct glucocorticoid-receptor-driven repression of inflammatory response genes in macrophages. <i>ELife</i> , 2018, 7, .	6.0	77
95	Hematopoietic stem cells made BETter by inhibition. <i>Haematologica</i> , 2018, 103, 919-921.	3.5	0
96	DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. <i>Molecular Cell</i> , 2018, 71, 592-605.e4.	9.7	114
97	Histone Native Chromatin Immunoprecipitation. <i>Methods in Molecular Biology</i> , 2018, 1832, 77-104.	0.9	5
98	RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 687-697.	8.2	123
99	BET Family Protein BRD4: An Emerging Actor in NF- κ B Signaling in Inflammation and Cancer. <i>Biomedicines</i> , 2018, 6, 16.	3.2	123
100	CBP/p300: intramolecular and intermolecular regulations. <i>Frontiers in Biology</i> , 2018, 13, 168-179.	0.7	7
101	The Co-operation of RUNX1 with LDB1, CDK9 and BRD4 Drives Transcription Factor Complex Relocation During Haematopoietic Specification. <i>Scientific Reports</i> , 2018, 8, 10410.	3.3	22
102	CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation. <i>Epigenetics and Chromatin</i> , 2018, 11, 30.	3.9	43
103	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. <i>Nature Communications</i> , 2018, 9, 3440.	12.8	80
104	Reassessing the Potential of Myb-targeted Anti-cancer Therapy. <i>Journal of Cancer</i> , 2018, 9, 1259-1266.	2.5	35
105	EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins. <i>Cancer Research</i> , 2018, 78, 4760-4773.	0.9	55
106	Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension. <i>Journal of Physiology</i> , 2019, 597, 1103-1119.	2.9	28
107	Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. <i>Circulation Research</i> , 2019, 125, 662-677.	4.5	105
108	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 460-468.	2.3	14

#	ARTICLE	IF	CITATIONS
109	Elevated H3K27ac in aged skeletal muscle leads to increase in extracellular matrix and fibrogenic conversion of muscle satellite cells. <i>Aging Cell</i> , 2019, 18, e12996.	6.7	35
110	BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. <i>Epigenetics and Chromatin</i> , 2019, 12, 39.	3.9	20
111	Non-canonical transcriptional consequences of BET inhibition in cancer. <i>Pharmacological Research</i> , 2019, 150, 104508.	7.1	7
112	Targeting transcription factors in cancer "from undruggable to reality". <i>Nature Reviews Cancer</i> , 2019, 19, 611-624.	28.4	515
113	Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications. <i>Cancers</i> , 2019, 11, 1483.	3.7	32
114	LSD1 inhibition by tranlycypromine derivatives interferes with GF11-mediated repression of PU.1 target genes and induces differentiation in AML. <i>Leukemia</i> , 2019, 33, 1411-1426.	7.2	53
115	Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 81.	3.7	59
116	Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 251.	8.6	27
117	Cluh plays a pivotal role during adipogenesis by regulating the activity of mitochondria. <i>Scientific Reports</i> , 2019, 9, 6820.	3.3	9
118	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. <i>Blood</i> , 2019, 134, 59-73.	1.4	75
119	Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside. <i>Molecular Cancer Research</i> , 2019, 17, 1417-1428.	3.4	52
120	The hyper-activation of transcriptional enhancers in breast cancer. <i>Clinical Epigenetics</i> , 2019, 11, 48.	4.1	42
121	Targeting chromatin complexes in fusion protein-driven malignancies. <i>Nature Reviews Cancer</i> , 2019, 19, 255-269.	28.4	55
122	Epigenetic therapies in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 130, 197-204.	1.9	23
123	Identification of a novel enhancer of CEBPE essential for granulocytic differentiation. <i>Blood</i> , 2019, 133, 2507-2517.	1.4	33
124	Emerging roles of and therapeutic strategies targeting BRD4 in cancer. <i>Cellular Immunology</i> , 2019, 337, 48-53.	3.0	86
125	Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies. <i>Blood Science</i> , 2019, 1, 50-56.	0.9	1
126	AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia. <i>Blood</i> , 2019, 134, 2183-2194.	1.4	25

#	ARTICLE	IF	CITATIONS
127	Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. <i>Blood</i> , 2019, 134, 2195-2208.	1.4	39
128	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. <i>Nature Communications</i> , 2019, 10, 5348.	12.8	58
129	Identification and characterization of cancer vulnerabilities via targeted protein degradation. <i>Drug Discovery Today: Technologies</i> , 2019, 31, 81-90.	4.0	25
130	c-MYB and DMTF1 in Cancer. <i>Cancer Investigation</i> , 2019, 37, 46-65.	1.3	28
131	Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. <i>Leukemia Research</i> , 2019, 77, 42-50.	0.8	16
132	Drugging transcription in heart failure. <i>Journal of Physiology</i> , 2020, 598, 3005-3014.	2.9	8
133	The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. <i>Cancer</i> , 2020, 126, 939-948.	4.1	25
134	Massively multiplex chemical transcriptomics at single-cell resolution. <i>Science</i> , 2020, 367, 45-51.	12.6	196
135	BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes. <i>Circulation</i> , 2020, 142, 2338-2355.	1.6	31
136	C/EBP β isoforms sequentially regulate regenerating mouse hematopoietic stem/progenitor cells. <i>Blood Advances</i> , 2020, 4, 3343-3356.	5.2	14
137	Beyond the genome: challenges and potential for epigenetics-driven therapeutic approaches in pulmonary arterial hypertension. <i>Biochemistry and Cell Biology</i> , 2020, 98, 631-646.	2.0	1
138	Synergistic antitumor activity of DHA and JQ1 in colorectal carcinoma. <i>European Journal of Pharmacology</i> , 2020, 885, 173500.	3.5	7
139	Chromatin Looping Shapes KLF5-Dependent Transcriptional Programs in Human Epithelial Cancers. <i>Cancer Research</i> , 2020, 80, 5464-5477.	0.9	24
140	LAMB3 promotes tumour progression through the AKT \leftrightarrow FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer. <i>Oncogene</i> , 2020, 39, 4666-4680.	5.9	46
141	Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation. <i>Nature Communications</i> , 2020, 11, 2243.	12.8	21
142	Transcriptional Control of Circadian Rhythms and Metabolism: A Matter of Time and Space. <i>Endocrine Reviews</i> , 2020, 41, 707-732.	20.1	66
143	Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. <i>Nature Reviews Cancer</i> , 2020, 20, 365-382.	28.4	87
144	Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation. <i>Epigenetics and Chromatin</i> , 2020, 13, 14.	3.9	17

#	ARTICLE	IF	CITATIONS
145	BRD4 Is Necessary for Differentiation Downstream of Epidermal Lineage-Determining Transcription Factors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2077-2081.e5.	0.7	9
146	Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors. <i>Scientific Reports</i> , 2020, 10, 2851.	3.3	19
147	The role of histone modifications in leukemogenesis. <i>Journal of Biosciences</i> , 2020, 45, 1.	1.1	4
148	Epigenetic Targeting of <i>TERT</i> -Associated Gene Expression Signature in Human Neuroblastoma with <i>TERT</i> Overexpression. <i>Cancer Research</i> , 2020, 80, 1024-1035.	0.9	11
149	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. <i>Haematologica</i> , 2020, 105, 2420-2431.	3.5	12
150	Perspectives in HPV Secondary Screening and Personalized Therapy Basing on Our Understanding of HPV-Related Carcinogenesis Pathways. <i>Mediators of Inflammation</i> , 2020, 2020, 1-7.	3.0	3
151	BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. <i>Circulation Research</i> , 2020, 126, 1190-1208.	4.5	88
152	Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 970-982.	5.2	16
153	Role of BET Inhibitors in Triple Negative Breast Cancers. <i>Cancers</i> , 2020, 12, 784.	3.7	15
154	Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of <i>Hoxa9</i> . <i>Blood</i> , 2021, 137, 75-88.	1.4	29
155	MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. <i>Cell Stem Cell</i> , 2021, 28, 33-47.e8.	11.1	31
156	Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response. <i>Neurobiology of Disease</i> , 2021, 148, 105217.	4.4	55
158	The E-Twenty-Six Family in Hepatocellular Carcinoma: Moving into the Spotlight. <i>Frontiers in Oncology</i> , 2020, 10, 620352.	2.8	0
160	Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia. <i>ELife</i> , 2021, 10, .	6.0	37
161	An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. <i>Cell Reports</i> , 2021, 34, 108744.	6.4	17
162	In Vivo CD8+ T cell CRISPR screening reveals control by <i>Fli1</i> in infection and cancer. <i>Cell</i> , 2021, 184, 1262-1280.e22.	28.9	107
163	Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. <i>Nucleic Acids Research</i> , 2021, 49, 4971-4988.	14.5	22
164	7-Ethyl-10-Hydroxycamptothecin, a DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth. <i>Frontiers in Pharmacology</i> , 2021, 12, 664176.	3.5	1

#	ARTICLE	IF	CITATIONS
165	Functional coordination of BET family proteins underlies altered transcription associated with memory impairment in fragile X syndrome. <i>Science Advances</i> , 2021, 7, .	10.3	7
166	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. <i>Molecular Cell</i> , 2021, 81, 2183-2200.e13.	9.7	59
167	C/EBP β is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. <i>Oncogene</i> , 2021, 40, 4746-4758.	5.9	14
168	Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia. <i>Cancer Discovery</i> , 2021, 11, 2868-2883.	9.4	25
169	Epigenetic deregulation in myeloid malignancies. <i>Blood</i> , 2021, 138, 613-624.	1.4	8
170	Cohesin Mutations in Cancer: Emerging Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6788.	4.1	22
171	Chromatin Mechanisms Driving Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2022, 14, a040956.	5.5	9
172	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	7.0	33
173	PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. <i>Blood</i> , 2021, 138, 1855-1869.	1.4	23
174	Intrinsically disordered Meningioma-1 stabilizes the BAF complex to cause AML. <i>Molecular Cell</i> , 2021, 81, 2332-2348.e9.	9.7	14
175	Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells. <i>PLoS Genetics</i> , 2021, 17, e1009708.	3.5	7
176	Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics. <i>Current Opinion in Oncology</i> , 2021, 33, 526-531.	2.4	9
177	Histone H3K4me1 and H3K27ac play roles in nucleosome eviction and eRNA transcription, respectively, at enhancers. <i>FASEB Journal</i> , 2021, 35, e21781.	0.5	31
178	Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 845-856.	2.3	2
179	Histone H3K4me1 strongly activates the DNase I hypersensitive sites in super-enhancers than those in typical enhancers. <i>Bioscience Reports</i> , 2021, 41, .	2.4	3
180	Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 518-531.	5.0	23
181	Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer. <i>Nature Communications</i> , 2021, 12, 4441.	12.8	49
182	Next generation epigenetic modulators to target myeloid neoplasms. <i>Current Opinion in Hematology</i> , 2021, 28, 356-363.	2.5	1

#	ARTICLE	IF	CITATIONS
183	FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. <i>Molecular Therapy</i> , 2021, 29, 2583-2600.	8.2	39
184	Post-translational lysine ac(et)ylation in health, ageing and disease. <i>Biological Chemistry</i> , 2022, 403, 151-194.	2.5	15
185	miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4. <i>Cancer Research</i> , 2021, 81, 5190-5201.	0.9	11
186	ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. <i>Molecular Cell</i> , 2021, 81, 3604-3622.e10.	9.7	32
187	The Functions of BET Proteins in Gene Transcription of Biology and Diseases. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 728777.	3.5	56
188	Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro. <i>iScience</i> , 2021, 24, 101989.	4.1	13
189	Supercharging BRD4 with NUT in carcinoma. <i>Oncogene</i> , 2021, 40, 1396-1408.	5.9	48
190	Oncogenic ETS Factors in Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1210, 409-436.	1.6	34
191	Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia. <i>Cell Reports</i> , 2020, 32, 108200.	6.4	20
192	BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. <i>Journal of Clinical Investigation</i> , 2016, 126, 3479-3494.	8.2	168
193	The natural anti-tumor compound Celastrol targets a Myb-C/EBP β -p300 transcriptional module implicated in myeloid gene expression. <i>PLoS ONE</i> , 2018, 13, e0190934.	2.5	27
194	Endoplasmic reticulum stress actively suppresses hepatic molecular identity in damaged liver. <i>Molecular Systems Biology</i> , 2020, 16, e9156.	7.2	22
195	BRD4 contributes to LPS-induced macrophage senescence and promotes progression of atherosclerosis-associated lipid uptake. <i>Aging</i> , 2020, 12, 9240-9259.	3.1	33
196	BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. <i>Oncotarget</i> , 2016, 7, 38319-38332.	1.8	43
197	Dependence on Myb expression is attenuated in myeloid leukaemia with N-terminal CEBPA mutations. <i>Life Science Alliance</i> , 2019, 2, e201800207.	2.8	6
198	Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. <i>ELife</i> , 2017, 6, .	6.0	56
199	lncRNA requirements for mouse acute myeloid leukemia and normal differentiation. <i>ELife</i> , 2017, 6, .	6.0	54
200	Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth. <i>Blood</i> , 2022, 139, 502-522.	1.4	23

#	ARTICLE	IF	CITATIONS
201	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. <i>Blood</i> , 2022, 139, 1080-1097.	1.4	16
202	Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. <i>Frontiers in Oncology</i> , 2021, 11, 760789.	2.8	7
211	Clinical efficacy of platelet transfusion therapy in patients with leukemia and analysis of risk factors for ineffective transfusion. <i>Oncology Letters</i> , 2020, 19, 2554-2561.	1.8	2
213	Myeloid transformation by <i>MLL</i> depends strictly on C/EBP. <i>Life Science Alliance</i> , 2021, 4, e202000709.	2.8	5
214	Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 3157-3178.	1.4	8
215	Emerging roles of bromodomain protein 4 in regulation of stem cell identity. <i>Stem Cells</i> , 2021, 39, 1615-1624.	3.2	5
216	A B-cell developmental gene regulatory network is activated in infant AML. <i>PLoS ONE</i> , 2021, 16, e0259197.	2.5	5
217	BET Inhibition Enhances TNF-Mediated Antitumor Immunity. <i>Cancer Immunology Research</i> , 2022, 10, 87-107.	3.4	8
218	Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia. <i>Molecular Cancer Research</i> , 2022, 20, 361-372.	3.4	22
219	KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. <i>Cancer Discovery</i> , 2022, 12, 792-811.	9.4	33
220	Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824. <i>BBA Advances</i> , 2022, 2, 100034.	1.6	2
222	C/EBP β sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module. <i>Experimental Hematology</i> , 2022, 108, 8-15.	0.4	6
223	CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. <i>Biochemical and Biophysical Research Communications</i> , 2022, 590, 49-54.	2.1	7
224	A synthetic covalent ligand of the C/EBP β transactivation domain inhibits acute myeloid leukemia cells. <i>Cancer Letters</i> , 2022, 530, 170-180.	7.2	8
225	Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. <i>Cancers</i> , 2022, 14, 43.	3.7	9
226	The role of histone modifications in leukemogenesis. <i>Journal of Biosciences</i> , 2020, 45, .	1.1	0
227	Role of NR4A family members in myeloid cells and leukemia. <i>Current Research in Immunology</i> , 2022, 3, 23-36.	2.8	6
228	Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer. <i>Cancers</i> , 2022, 14, 1118.	3.7	10

#	ARTICLE	IF	CITATIONS
229	Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit. <i>Cancers</i> , 2022, 14, 1561.	3.7	5
230	Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. <i>Nature Communications</i> , 2022, 13, 1434.	12.8	17
231	Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML). <i>Genes and Diseases</i> , 2022, 9, 1466-1477.	3.4	5
232	Natural Products with Antitumor Potential Targeting the MYB-C/EBP β -p300 Transcription Module. <i>Molecules</i> , 2022, 27, 2077.	3.8	5
234	Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1852.	3.7	3
235	Emerging roles of BET proteins in transcription and co-transcriptional RNA processing. <i>Wiley Interdisciplinary Reviews RNA</i> , 2023, 14, e1734.	6.4	8
236	Identification of (S)-10-Hydroxycamptothecin as a potent BRD4 inhibitor for treating triple-negative breast cancer. <i>Journal of Molecular Structure</i> , 2022, 1265, 133366.	3.6	2
237	MYB-NFIB fusion transcript in adenoid cystic carcinoma: Current state of knowledge and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 176, 103745.	4.4	16
238	Direct targeted therapy for MLL fusion-driven high-risk acute leukaemias. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	5
239	Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents. <i>Theranostics</i> , 2022, 12, 4935-4948.	10.0	38
240	A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. <i>Pathology and Oncology Research</i> , 0, 28, .	1.9	7
244	JQ1 attenuates neuroinflammation by inhibiting the inflammasome-dependent canonical pyroptosis pathway in SAE. <i>Brain Research Bulletin</i> , 2022, 189, 174-183.	3.0	11
245	EVI1 drives leukemogenesis through aberrant ERG activation. <i>Blood</i> , 2023, 141, 453-466.	1.4	11
246	Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
248	Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia. <i>IScience</i> , 2022, 25, 105139.	4.1	1
249	Regulation of KDM5C stability and enhancer reprogramming in breast cancer. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	2
250	Dual inhibition of BET and HAT/p300 suppresses colorectal cancer via DR5- and p53/PUMA-mediated cell death. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
251	Inhibition of bromodomain-containing protein 4 enhances the migration of esophageal squamous cell carcinoma cells by inducing cell autophagy. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 2340-2352.	2.0	2

#	ARTICLE	IF	CITATIONS
252	Effects of the omega-3 fatty acid DHA on histone and p53 acetylation in diffuse large B cell lymphoma. <i>Biochemistry and Cell Biology</i> , 2023, 101, 172-191.	2.0	1
253	MYB and ELF3 differentially modulate labor-inducing gene expression in myometrial cells. <i>PLoS ONE</i> , 2023, 18, e0271081.	2.5	2
254	Protein acylation: mechanisms, biological functions and therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	21
256	Cre recombinase expression cooperates with homozygous FLT3 internal tandem duplication knockin mouse model to induce acute myeloid leukemia. <i>Leukemia</i> , 2023, 37, 741-750.	7.2	1
257	C/EBP β cooperates with MYB to maintain the oncogenic program of AML cells. <i>Oncotarget</i> , 2023, 14, 174-177.	1.8	1
260	Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. <i>Molecular Cancer Research</i> , 2023, 21, 631-647.	3.4	2
261	Streamlined DNA-encoded small molecule library screening and validation for the discovery of novel chemotypes targeting BET proteins. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 32, 637-649.	5.1	1
262	RUNX1 colludes with NOTCH1 to reprogram chromatin in T β cell acute lymphoblastic leukemia. <i>IScience</i> , 2023, 26, 106795.	4.1	4
263	Establishment of environment-sensitive probes targeting BRD3/BRD4 for imaging and therapy of tumor. <i>European Journal of Medicinal Chemistry</i> , 2023, 257, 115478.	5.5	1
264	Review on: BRD4 inhibitors for anticancer research. , 2023, 37, 201196.		0
265	Molecular Dynamics Simulations Combined with Markov Model to Explore the Effect of Allosteric Inhibitor Binding on Bromodomain-Containing Protein 4. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10831.	4.1	1
266	Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition. <i>Nature Chemical Biology</i> , 2023, 19, 1215-1222.	8.0	5
267	Biophysical ordering transitions underlie genome 3D re-organization during cricket spermiogenesis. <i>Nature Communications</i> , 2023, 14, .	12.8	2
268	Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping. <i>EMBO Reports</i> , 2023, 24, .	4.5	1
269	Cell β -specific tumour sensitivity identified with a bromodomain targeting <sc>PROTAC</sc> in adenoid cystic carcinoma. <i>Journal of Pathology</i> , 2024, 262, 37-49.	4.5	0
270	Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
271	ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K/AKT/mTOR/p70S6k and MAPK signaling pathways. <i>Neoplasia</i> , 2023, 45, 100936.	5.3	1
272	The bromodomain acyl-lysine readers in human health and disease. , 2024, , 57-97.		0

#	ARTICLE	IF	CITATIONS
273	ETV4-Dependent Transcriptional Plasticity Maintains <i>MYC</i> Expression and Results in IMiD Resistance in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2024, 5, 56-73.	5.0	2
274	Protein therapeutics as an emerging strategy to deal with skin cancer: A short review. <i>Experimental Dermatology</i> , 2024, 33, .	2.9	0
275	Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBP β) and SPI1 (PU.1). <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2024, 1867, 195004.	1.9	1
276	Lysine acetyltransferase 6A maintains CD4+ T cell response via epigenetic reprogramming of glucose metabolism in autoimmunity. <i>Cell Metabolism</i> , 2024, 36, 557-574.e10.	16.2	0
277	PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells. <i>Science Advances</i> , 2024, 10, .	10.3	0
279	TEA domain transcription factor 1 (TEAD1) induces cardiac fibroblasts cells remodeling through BRD4/Wnt4 pathway. <i>Signal Transduction and Targeted Therapy</i> , 2024, 9, .	17.1	0
280	Transcription Factor MYB as Therapeutic Target: Current Developments. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3231.	4.1	0